Compound |
GI50(m mol L-1 )
|
|
MCF-7 |
NCI-H460 |
SF-268 |
3a |
30 ± 0.6 |
17.3 ± 1.4 |
22.3 ±1.5 |
3b |
20 ± 0.4 |
24.3 ± 0.8 |
32 ± 0.8 |
5 |
70.6 ± 16.9 |
38.9 ± 10.8 |
50.8 ± 8.6 |
6 |
40.6 ± 12.2 |
32.6 ± 8.6 |
60.4 ± 14.8 |
7 |
0.4 ± 0.2 |
0.1 ± 0.08 |
0.9 ± 0.08 |
9 |
11.8 ± 0.6 |
14.5 ± 0.8 |
16.7 ± 1.6 |
12 |
72.7 ± 17.5 |
40.2 ± 12.8 |
50.0 ± 9.01 |
14 |
50.1 ± 0.7 |
23.2 ± 4.8 |
18.4 ± 1.8 |
17a |
22.0 ± 0.2 |
30.6 ± 1.4 |
38.4 ± 0.6 |
17b |
38.0 ± 1.8 |
44.0 ± 0.8 |
20.5 ± 1.1 |
19a |
20.0 ± 0.6 |
22.0 ± 0.4 |
31.5 ± 8.0 |
19b |
0.01 ± 0.006 |
0.04 ± 0.002 |
0.03 ± 0.005 |
21 |
70.9 ± 0.9 |
43.6 ± 1.8 |
56.8 ± 0.8 |
22 |
0.02 ± 0.009 |
0.06 ± 0.008 |
0.08 ± 0.001 |
Doxorubicin |
0.04 ± 0.008 |
0.09 ± 0.008 |
0.09 ± 0.007 |
|
| Results are given in concentrations that were able to cause 50 % of cell growth
inhibition (GI50) after a continuous exposure of 48 h and show means ± SEM of
three-independent experiments performed in duplicate. |
| Table 1: Effect of compounds 3a-21b on the growth of three human tumor cell
lines. |
